A recent RAND report reveals that the gross price of insulin in the United States surpasses that of 33 high-income nations by more than nine times. This stark contrast persists even after accounting for rebates and discounts, with U.S. prices remaining 2.3 times higher on average.

Insulin, crucial for managing insulin-dependent diabetes, has witnessed a significant surge in list prices in the U.S. since the early 2010s. Between 2012 and 2016, federal analysis shows an annual increase of 15% to 17% in the average wholesale-acquisition price for various types of insulin.

The study emphasizes the sustained and substantial escalation of insulin prices in the U.S. compared to other middle- and high-income nations.

Despite ongoing efforts to address rising healthcare costs, insulin remains a focal point of concern, impacting individuals paying out of pocket and those covered under Medicare.

The analysis, based on industry data from 2017 to 2022, highlights the consistent disparity in insulin prices between the U.S. and OECD member countries.

As the U.S. grapples with efforts to make insulin more affordable, the study underscores the pressing need for sustainable solutions to address this critical healthcare challenge.